---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000056"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-10-14T11:21:15+00:00"
generated_at: "2026-10-14T11:25:05.568718+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aquestive licenses LIBERVANT seizure-cluster film to Eton for $10M upfront, up to $47.5M milestones

## Summary
- Aquestive received a $10.0M upfront license fee from Eton for exclusive U.S. rights to LIBERVANT (diazepam) buccal film for epilepsy seizure clusters.
- Up to $47.5M milestones: $10M at first U.S. commercial sale (cut to $5M absent full FDA approval for ages 2-5), $2.5M for ages 6-11, $35M on net sales.
- Aquestive also gets mid-teens royalties on U.S. net sales and serves as exclusive manufacturer under a 20-year supply agreement.
- LIBERVANT holds FDA tentative approval; full approval for ages 12+ expected after VALTOCO orphan exclusivity lapses Jan 10, 2027; launch targeted April 2027.
- Type 9 NDA to add ages 6-11 has a PDUFA date of March 29, 2027; U.S. seizure rescue market exceeds $450M annually.

## SEC filing metadata
- accession: 0001398733-26-000056
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-10-14T11:21:15+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000056/0001398733-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000056/aqst-20261013.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000056
- JSON: https://secwatch.observer/filing/0001398733-26-000056.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.